Good evening :)
Place Order
Add to Watchlist

Caplin Point Laboratories Ltd

CAPLIPOINT

Caplin Point Laboratories Ltd

CAPLIPOINT
Health CarePharmaceuticals
SmallcapWith a market cap of ₹17,957 cr, stock is ranked 377
High RiskStock is 3.04x as volatile as Nifty
2,354.651.09% (-25.85)
2,354.651.09% (-25.85)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹17,957 cr, stock is ranked 377
High RiskStock is 3.04x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹17,957 cr, stock is ranked 377
High RiskStock is 3.04x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
36.387.650.21%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Caplin Point Laboratories Limited is a pharmaceutical company. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management and Anti-ulcers.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 21.41%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.3% to 0.47%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 20.95%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue242.38411.61552.51667.72904.531,084.831,308.161,522.791,761.311,904.68
Raw Materialssubtract121.84184.78240.57298.85608.26389.39589.43710.15798.731,226.80
Power & Fuel Costsubtract7.569.9110.9813.7614.8116.3621.4025.5333.57
Employee Costsubtract18.4730.8139.1447.1167.76102.53115.30136.99143.59
Selling & Administrative Expensessubtract12.6032.0438.3948.6386.26108.30133.40140.10168.75
Operating & Other expensessubtract14.0419.3015.448.49-173.96116.0715.2112.90-1.98
Depreciation/Amortizationsubtract7.4813.3019.0023.4331.6236.9746.9044.9953.4463.02
Interest & Other Itemssubtract0.340.520.610.580.321.590.700.780.780.58
Taxes & Other Itemssubtract14.2825.3443.5950.3154.4671.3585.9875.09107.34120.72
EPS6.0612.6519.1523.3528.4332.0339.6049.6160.2164.99
DPS1.201.502.002.202.503.004.004.505.005.00
Payout ratio0.200.120.100.090.090.090.100.090.080.08

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Caplin Point Laboratories Ltd39.297.650.21%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare CAPLIPOINT with any stock or ETF
Compare CAPLIPOINT with any stock or ETF
CAPLIPOINT
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.56%1.62%0.22%3.70%23.90%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep2.69%3.09%2.85%3.34%3.37%3.70%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Caplin Point Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
UTI Small Cap Fund - Direct Growth Plan

Growth
0.4735%1.83%0.22%8/98 (+40)
UTI Aggressive Hybrid Fund - Growth - Direct Plan

Growth
0.3393%1.00%0.14%59/104 (+3)
UTI Large & Mid Cap Fund - Growth - Direct Plan

Growth
0.2387%1.06%0.14%50/68 (+4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Increasing Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

CAPLIPOINT has increased dividends consistently over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.21%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.11 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateMay 31, 2024

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

May 31, 2024

Cash Dividend

Ex DateEx DateSep 14, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 14, 2023

Cash Dividend

Ex DateEx DateJun 9, 2023

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Jun 9, 2023

Cash Dividend

Ex DateEx DateSep 21, 2022

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 21, 2022

News & Opinions
Earnings
Caplin Point Laboratories consolidated net profit rises 13.87% in the September 2024 quarter

Net profit of Caplin Point Laboratories rose 13.87% to Rs 130.80 crore in the quarter ended September 2024 as against Rs 114.87 crore during the previous quarter ended September 2023. Sales rose 17.81% to Rs 483.10 crore in the quarter ended September 2024 as against Rs 410.06 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales483.10410.06 18 OPM %34.0833.51 - PBDT185.22157.76 17 PBT168.46146.00 15 NP130.80114.87 14 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Caplin Point Laboratories to hold board meeting

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Volumes spurt at Caplin Point Laboratories Ltd counter

Hindustan Zinc Ltd, Godfrey Phillips India Ltd, Angel One Ltd, Triveni Engineering and Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 19 August 2024.Caplin Point Laboratories Ltd registered volume of 42.47 lakh shares by 14:14 IST on NSE, a 22.69 fold spurt over two-week average daily volume of 1.87 lakh shares. The stock rose 12.37% to Rs.1,781.60. Volumes stood at 70156 shares in the last session.Hindustan Zinc Ltd witnessed volume of 206.02 lakh shares by 14:14 IST on NSE, a 8.34 times surge over two-week average daily volume of 24.70 lakh shares. The stock dropped 4.49% to Rs.496.55. Volumes stood at 113.19 lakh shares in the last session.Godfrey Phillips India Ltd clocked volume of 8.7 lakh shares by 14:14 IST on NSE, a 6.44 times surge over two-week average daily volume of 1.35 lakh shares. The stock gained 11.08% to Rs.5,038.10. Volumes stood at 2.37 lakh shares in the last session.Angel One Ltd saw volume of 34.87 lakh shares by 14:14 IST on NSE, a 6.44 fold spurt over two-week average daily volume of 5.42 lakh shares. The stock increased 8.76% to Rs.2,349.45. Volumes stood at 3.85 lakh shares in the last session.Triveni Engineering and Industries Ltd notched up volume of 60.1 lakh shares by 14:14 IST on NSE, a 6.13 fold spurt over two-week average daily volume of 9.81 lakh shares. The stock rose 9.09% to Rs.453.00. Volumes stood at 5.41 lakh shares in the last session.Powered by Capital Market - Live

3 months agoCapital Market - Live
Live Market Update
Benchmarks trades with small gains; media shares in demand

The domestic equity benchmarks traded with decent gains in morning trade. The Nifty traded above the 24,550 mark. Media shares advanced for the second consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex, rose 20.55 points or 0.03% to 80,460.37. The Nifty 50 index added 18 points or 0.07% to 24,559.15. The broader market outperformed the frontline indices, the S&P BSE Mid-Cap index added 0.52% and the S&P BSE Small-Cap index gained 1.19%. The market breadth was strong. On the BSE, 2,643 shares rose and 1,031 shares fell. A total of 160 shares were unchanged. Economy: India's forex reserves declined $4.8 billion to $670.119 billion for the week ended August 9, according to the latest RBI data. In the previous reporting week, the country's foreign exchange reserves had increased $7.533 billion to an all-time high of $674.919 billion. For the week ended August 9, foreign currency assets, a major component of the reserves, decreased by $4.079 billion to $587.96 billion. Gold reserves declined by $860 million to $59.239 billion during the week. The special drawing rights (SDRs) were up by $121 million to $18.282 billion. India's reserve position with the IMF increased by $18 million to $4.638 billion in the reporting week, the central bank data showed. Buzzing Index: The Nifty Media index added 2.17% to 2,104.35. The index advanced 4.31% in the two trading sessions. V18 Broadcast (up 4.21%), Network 18 Media & Investments (up 3.05%), Saregama India (up 2.64%), PVR Inox (up 2.6%), Hathway Cable & Datacom (up 1.78%), Tips Industries (up 1.75%), Dish TV India (up 1.24%), Zee Entertainment Enterprises (up 1.15%), Nazara Technologies (up 0.55%) and Sun TV Network (up 0.21%) edged higher. Stocks in Spotlight: Caplin Point Laboratories soared 8.40% after the Brazilian Health Regulatory Agency (ANVISA) conducted inspection at its Chennai facility between 12 and 16 August 2024 and concluded with zero observations. Techno Electric & Engineering Company (Techno Electric) hits upper circuit of 5% after the company partnered with IndiGrid to develop two IndiGrid's Greenfield interstate transmission Systems (ISTS) projects. Glenmark Pharmaceuticals added 2.89% after the company's subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Caplin Point hits life high after Chennai unit clears Brazilian Agency's inspection

ANVISA conducted an inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi between 12 and 16 August 2024 and concluded with zero observations. Chairman, C.C.Paarthipan said, 'It is indeed gratifying to have two back to back audits with zero observations. We remain steadfast in our commitment to maintaining the highest levels of quality compliance at all our sites. Brazil is an important part of our expansion plans in Latin America and this clearance opens the door to the largest market in that geography.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms. The company's consolidated net profit jumped 19.8% to Rs 124.92 crore on 16.1% increase in revenue from operations to Rs 458.96 crore in Q1 FY25 over Q1 FY24. The scrip hit all time high of Rs 1,732.80 in today's intraday session. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Caplin Point Chennai unit clears Brazilian Agency's inspection

Caplin Point Laboratories informed that ANVISA conducted an inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi, in Chennai in Tamil Nadu. Chairman Mr.C.C.Paarthipan added 'It is indeed gratifying to have two back to back audits with Zero observations. We remain steadfast in our commitment to maintaining the highest levels of quality compliance at all our sites. Brazil is an important part of our expansion plans in Latin America and this clearance opens the door to the largest market in that geography.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms. The company's consolidated net profit jumped 19.8% to Rs 124.92 crore on 16.1% increase in revenue from operations to Rs 458.96 crore in Q1 FY25 over Q1 FY24. Shares of Caplin Point Laboratories added 1.68% to end at Rs 1,585.75 on Friday, 16 August 2024. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Board of Caplin Point Laboratories recommends final dividend

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 125%) , subject to the approval of the shareholders.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Caplin Point Laboratories to convene AGM

Caplin Point Laboratories announced that the 33th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Caplin Point Laboratories consolidated net profit rises 19.86% in the June 2024 quarter

Net profit of Caplin Point Laboratories rose 19.86% to Rs 123.97 crore in the quarter ended June 2024 as against Rs 103.43 crore during the previous quarter ended June 2023. Sales rose 16.10% to Rs 458.96 crore in the quarter ended June 2024 as against Rs 395.32 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales458.96395.32 16 OPM %33.0832.01 - PBDT170.34138.37 23 PBT154.38126.99 22 NP123.97103.43 20 Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Caplin Point rallies after Q1 PAT climbs 20% YoY to Rs 125 cr

Profit before tax (PBT) increased 21.6% YoY to Rs 154.38 crore in Q1 FY25. EBITDA jumped to Rs 170.37 crore in Q1 FY25, registering the growth of 23% YoY, aided by new products launches. EBITDA margin stood at 35.7% in Q1 FY25 as against 34% in Q1 FY24. The company's LatAM business shows strong revenue and bottom-line growth with robust cashflows. Branded generic segment drives growth in profitability with specialty products including Softgels and Pre-Filled Syringes. The generics segment contributes 70% of the company's revenue while branded generics segment contributes 30%. Caplin One Labs Oncology site commences exports to LatAm, Company targets breakeven revenue within next 12 months. Product registration work ongoing in 7 countries in LatAm including Mexico. In US & regulated markets, Caplin Steriles records impressive revenue growth through enhanced automation and improved productivity. Caplin Steriles USA Inc. will launch first products by October 2024 and plans to launch 35 products in 12 months. The company said that it has allocated an overall Capex budget of approximately Rs 600-650 crore for the investment projects, most of which are nearing completion. The intended Capex aims to enhance existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process. C.C. Paarthipan, Chairman said, 'Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We're pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we're now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.Powered by Capital Market - Live

3 months agoCapital Market - Live